BMW, Ford and Honda Name CEO of EV-Grid Integration Joint Venture
By Michael Susin
BMW, Ford and Honda said Wednesday they started operations of their equally-owned joint venture ChargeScape, and appointed Joseph Vellone as its first chief executive officer.
The automakets said they Vellone has 15 years of experience in the energy and climate sectors, having been most recently part of the founding team at software start-up ev.energy.
The company also appointed Kalidindi Raju as chief technology officer. Raju has over 15 years of experience in the technology sector, previously serving in senior leadership positions at Amazon, OATI, among others.
The companies previously announced the partnership on Sept. 2023, and said then the joint-venture was expected to be operational early 2024 subject to regulatory clearance.
ChargeScape is a software platform that integrates electric vehicles into the power grid in order to improve grid stability by temporarily reducing demand when the grid is constrained and even sending energy back into the power grid when needed, offering a cost-efficient operational benefit for electric utilities.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
September 18, 2024 09:28 ET (13:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks